EGFR和HER2在胶质瘤复发前后表达的变化

Expression of EGFR and HER2 in paired primary and recurrent astrocytic tumors

目的探讨EGFR和HER2在胶质瘤复发中的意义。方法采用免疫组织化学方法(SABC法)观察24例复发胶质瘤患者原发肿瘤和复发肿瘤组织中EGFR和HER2的表达并与临床治疗指标进行相关分析。结果复发肿瘤组织较原发肿瘤组织中的EGFR表达减少(P=0.002),复发肿瘤组织较原发肿瘤组织中的HER2表达增加(P=0.006)。原发肿瘤中EGFR表达增高和患者无症状生存期呈显著正相关(Spearman等级相关系数r=0.441,P=0.031)。复发肿瘤中,EGFR表达增加和首次术后放疗呈正相关(Spearman等级相关系数r=0.446,P=0.029),HER2表达增加和首次术后化疗呈正相关(r=0.438,P=0.032)。结论 EGFR和HER2在胶质瘤复发前后的表达有统计学差异,且与术后治疗因素的选择有相关关系。

Objective To investigate whether EGFR and HER2 were differentially expressed in paired primary and recurrent astrocytic tumors.Methods Protein expression of EGFR and HER2 was investigated by SABC immunohistochemistry.An attempt was made to correlate expression data with clinical treatment factors.Results Decreased EGFR expression（P=0.002） and increased HER2 expression（P=0.006） were observed in recurrent astrocytic tumors compared with primary astrocytic tumors.In primary astrocytic tumors,increased EGFR expression was positively correlated with a longer progression-free survival（Spearman rank correlation coefficient r=0.441,P=0.031）.In recurrent astrocytic tumors,increased EGFR expression corresponded to the use of radiotherapy（Spearman rank correlation coefficient r=0.446,P=0.029） and increased HER2 expression corresponded to the use of chemotherapy（r=0.438,P=0.032）.Conclusion Expressions of EGFR and HER2 are different in paired primary and recurrent astrocytic tumors,and these differences could be caused by the different postoperative treatments used.